Brendan Curti

h-index
h10-index
h5-index

Research activity per year

Fingerprint

Dive into the research topics where Brendan Curti is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

2 Active
3 Finished

Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
Curti, B. (PI) & Redmond, W. (CoPI)
National Cancer Institute
08/2/21 → 07/31/25
Project: Research
Augmenting OX40 Immunotherapy in Men with Advanced Prostate Cancer
Curti, B. (PI)
Prostate Cancer Foundation
01/1/10 → …
Project: Research
Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma
Curti, B. (PI) & Redmond, W. (CoPI)
National Cancer Institute
07/6/15 → 06/30/16
Project: Research
Clinical and Immunological Effects of SBRT and IL-2 in Metastatic Melanoma
Crittenden, M. (PI) & Curti, B. (CoPI)
National Cancer Institute
04/1/13 → 03/31/16
Project: Research
Clinical Development of anti-OX40 and OX40L
Curti, B. (PI)
National Cancer Institute
07/1/04 → 04/30/10
Project: Research

76 Article
24 Other contribution
9 Review article
4 Chapter
More

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers
Algazi, A. P., Moon, J., Lao, C. D., Chmielowski, B., Kendra, K. L., Lewis, K. D., Gonzalez, R., Kim, K., Godwin, J. E., Curti, B. D., Latkovic-Taber, M., Lomeli, S. H., Gufford, B. T., Scumpia, P. O., Lo, R. S., Othus, M. & Ribas, A., May 15 2024, In: Cancer. 130, 10, p. 1784-1796 13 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab
Gogas, H., Ravimohan, S., Datta, A., Chhibber, A., Couselo, E. M., Diab, A., Pereira, C., Quéreux, G., Sandhu, S., Curti, B., Khushalani, N. I., Taylor, M. H., Daniels, G. A., Spreafico, A., Meniawy, T., Van Den Eertwegh, A. J. M., Sun, Y., Arriaga, Y., Zhou, M. & Long, G. V. & 1 others, Lebbé, C., Dec 2024, In: npj Precision Oncology. 8, 1, 150.
Research output: Contribution to journal › Article › peer-review

Open Access
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)
Tannir, N. M., Formiga, M. N., Penkov, K., Kislov, N., Vasiliev, A., Gunnar Skare, N., Hong, W., Dai, S., Tang, L., Qureshi, A., Zalevsky, J., Tagliaferri, M. A., George, D., Agarwal, N., Pal, S., Marathe, O., Curti, B., Hussain, A., Bilen, M. A. & Pal, S. K. & 93 others, Tannir, N. M., Uchio, E., Nair, S., Zuniga, R., Clark, W., Agarwal, N., Tester, W., Franks, E., Patel, K., Barata, P. C., Sharma, J. N., Radhi, S., Joshi, M., Parnis, F., Gurney, H., Zielinski, R., Guminski, A., Campbell, D., Fu, S., Vasiliev, A., Kopyltsov, E., Penkov, K., Gladkov, O., Perlin, D., Nosov, D., Kheifets, V., Lifirenko, I., Varlamov, S., Kislov, N., Karyakin, O., Zhiltsova, E., Fadeeva, N., Kahl, S., Kowalyszyn, R., Pilnik, N., Amuchastegui, V. A., Pastor, A., Vázquez, R., Lucas Kaen, D., Brown Arnold, M. A., Palazzo, F. S., Jarchum, G., Pfluger, Y., Salinas, J., Re, J. P., Jobim De Azevedo, S., Fay, A. P., Kussumoto, C., Rocha, R. O., Ferreira, U., Jose Da Fonseca Vinholes, J., Girotto, G. C., Lopes Dos Santos, V. M., Nirvana Da Cruz Formiga, M., Zereu, M., De Cassia Costamilan, R., D'Almeida Preto, D., Holanda Soares, J. P., Skare, N. G., Kann, A. G., Guimaraes, R. C., Patricia Dos Santos Martins, S., Azambuja, A. A., Lopes Nogueira, J. A., Brust, L., Martins Segalla, J. G., De Liz Vassen Schurmann, M., Franke, F. A., Sales, S. C., De Castro Monteiro, D., Marinho Dos Santos, G., Cesar De Andrade Mota, A., Martinez Lira, J. L., Bernal, E. T., Bailon, D. A., Alvarez, I. M., Soto, F. M., Acevedo Zanabria, C. L., Torrejon, A. F., Zorrilla Silvera, J. D., Salas Rojas, R. M., Panay, S., Acevedo Gaete, A. A., Gorena Palominos, M. A., Salman Boghikian, P. V., De Las Nieves Loredo Fort, E., Orellana Ulunque, E. A., Hornig Epple, V. I., Elqueta Pinochet, S. F., Peng, T. S. I., Sing, N. Q., Crilley, P. & Ghani, M., Aug 10 2024, In: Journal of Clinical Oncology. 42, 23, p. 2800-2811 12 p.
Research output: Contribution to journal › Article › peer-review
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
The CLEAR Trial Investigators, Apr 10 2024, In: Journal of Clinical Oncology. 42, 11, p. 1222-1228 7 p.
Research output: Contribution to journal › Article › peer-review

Open Access
13 Scopus citations
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
PRESTO Study Investigators, Apr 1 2024, In: Journal of Clinical Oncology. 42, 10, p. 1114-1123 10 p.
Research output: Contribution to journal › Article › peer-review
7 Scopus citations

Brendan Curti, MD

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response

Augmenting OX40 Immunotherapy in Men with Advanced Prostate Cancer

Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma

Clinical and Immunological Effects of SBRT and IL-2 in Metastatic Melanoma

Clinical Development of anti-OX40 and OX40L

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers

Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab

Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)

Brendan Curti, MD

Fingerprint

Collaborations and top research areas from the last five years

Grants

Research Output